Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2024-07-31 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Conference Call Q2 Results 2024, Fresenius
Investor Presentation Classification · 100% confidence The document is a detailed slide deck titled 'Fresenius Q2/24 Results' dated 31 July 2024. It contains financial highlights, business unit performance (Kabi and Helios), operational updates, and forward-looking guidance. It is a comprehensive presentation used by management to communicate quarterly financial results to investors, which fits the definition of an Investor Presentation (IP).
2024-07-31 English
Half-yearly financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Financial Report' for Fresenius, covering the first half of 2024. It contains comprehensive financial statements (income, cash flow, balance sheet), segment reporting, and a management report. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H2 2024
2024-07-31 English
Conference Call FY 2023, Fresenius
Investor Presentation Classification · 100% confidence The document is a detailed slide deck titled 'FY/23 Results' from Fresenius SE & Co. KGaA, dated 21 February 2024. It contains comprehensive financial performance data, operational updates, segment-specific analysis (Kabi, Helios, Vamed), and forward-looking guidance for FY/24. It is clearly an investor-facing presentation detailing financial results and strategy, which fits the definition of an Investor Presentation.
2024-05-28 English
Q1 statement / Q1 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Financial Report' for Q1 2024, containing detailed financial statements (Consolidated statement of income, financial position, cash flows), management discussion and analysis (Interim Group Management Report), and operational performance metrics. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-14 English
Conference Call Q1 Results 2024, Fresenius
Investor Presentation Classification · 100% confidence The document is a detailed slide deck titled 'Q1/24 Results' from Fresenius SE & Co. KGaA. It contains financial highlights, business updates, segment performance (Kabi, Helios, Vamed), and forward-looking guidance. It is clearly an investor-facing presentation used to communicate quarterly financial results and strategic updates, which fits the definition of an Investor Presentation.
2024-05-08 English
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Earnings Release Classification · 100% confidence The document is a short announcement dated May 7, 2024, titled "Fresenius raises outlook for fiscal year 2024." It explicitly states it is an 'Ad-hoc' disclosure of 'inside information' under MAR regulation. The content focuses on raising guidance for revenue growth and EBIT for the fiscal year 2024, providing specific percentage ranges. This is a preliminary announcement of financial expectations/changes, not the full quarterly report (IR) or the annual report (10-K). It fits best under the 'Earnings Release' category (ER) as it communicates updated financial performance expectations, although it is an outlook update rather than a final result release. Given the options, ER is the closest fit for a material financial guidance update. FY 2024
2024-05-07 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.